MedTrace Logo

Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03965429 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1020

Last updated 2025-06-15

No results posted yet for this study

Summary

Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.

Conditions

  • Malignant Hemopathy

Interventions

OTHER

Blood samples (additional tubes from care) longitudinal

Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).

OTHER

Blood samples (additional tubes from care) at inclusion

In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made. In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.

Sponsors & Collaborators

  • INSERM-U1068

    collaborator UNKNOWN

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • Raynier Devillier, MD, PhD · Institut Paoli-Calmettes

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-14
Primary Completion
2029-05-14
Completion
2029-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03965429 on ClinicalTrials.gov